The XPO1 inhibitor leptomycin B (LMB) and KPT-330 consistently downregulated Mcl-1 but not Bcl-2 or Bcl-xL in a dose-dependent manner in U87 and U251 glioblastoma cells and H1299 NSCLC cells (Fig. 1a, b). This evidence concerns the gene BCL2L1 and non-small cell lung carcinoma.